Kim Julie So-Young
President and CEO
Kim Julie So-Young has filed 3 SEC Form 4 filings (4 transaction rows) across 1 company, with disclosures dating back to 2026. 3 of those filings fall inside the rolling window. Most recent filing: Aug 13, 2026.
On the most recent filing, Kim Julie So-Young is listed as President and CEO at TAKEDA PHARMACEUTICAL CO LTD. Inside the rolling window, Kim Julie So-Young reported no open-market purchases and 1 open-market sale totaling $1.5M in TAK.
Companies traded
Other insiders at TAK
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$1.5M
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Kim Julie So-Young made?
Kim Julie So-Young has filed 3 SEC Form 4 filings (4 transaction rows) across 1 company since 2026.
Which companies does Kim Julie So-Young trade?
Kim Julie So-Young has filed SEC Form 4 disclosures for 1 company, including TAK.
When was Kim Julie So-Young's most recent SEC Form 4 filing?
Kim Julie So-Young's most recent SEC Form 4 filing on Tracefour is dated Aug 13, 2026.
What is Kim Julie So-Young's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Kim Julie So-Young is listed as President and CEO.
What is Kim Julie So-Young's total buy and sell value in the current window?
Inside the rolling retention window, Kim Julie So-Young bought $0 and sold $1.5M based on SEC Form 4 filings.
What was Kim Julie So-Young's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 89,090 TAK shares on 2026-08-10, worth $1.5M, per SEC Form 4 filings.